Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1

NCT06333808 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06333808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06333808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 25, 2024
Completion date
December 31, 2029
Enrollment
577 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection